Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer.
- Author:
Chang-Cheng SUN
1
;
Wei ZHENG
;
Chui-Ze KONG
;
Xia WANG
;
Chun-Ming YANG
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Aged, 80 and over; Biomarkers, Tumor; blood; Case-Control Studies; Chromogranin A; blood; Enzyme-Linked Immunosorbent Assay; Humans; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; blood; Prostatic Neoplasms; diagnosis; Sensitivity and Specificity
- From: National Journal of Andrology 2006;12(10):904-909
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the significance of the combined assay of chromogranin A (CgA) and prostate specific antigen (PSA) in the diagnosis of prostate cancer.
METHODSSerum CgA and PSA were detected by ELISA technique in 55 cases of prostate cancer (PCa), 25 cases of benign prostate hyperplasia (BPH), and 50 cases of normal subjects (control).
RESULTSThe serum CgA level in the PCa group was significantly higher than those in the control and BPH groups (P < 0.05), and increased with clinical stages. The parallel and serial tests associated with serum PSA and CgA raised the rate of detection of prostate cancer.
CONCLUSIONThe combined assay of serum PSA and CgA is of significant clinical value in raising the rate of diagnosis of prostate cancer, as well as in staging and prognosing the disease.
